IMPlementation of gUideLines for the Management of Arterial hypertenSION. The IMPULSION Study (IMPULSION)

This study has been completed.
Information provided by:
Hellenic Atherosclerosis Society Identifier:
First received: December 23, 2006
Last updated: January 28, 2009
Last verified: January 2009
The objective of this protocol is to improve awareness, treatment, and control of arterial hypertension, within primary prevention of target organ damage, by implementing guidelines, after training of the participating physicians.

Condition Intervention Phase
High Blood Pressure
Behavioral: Implementation of guidelines
Phase 4

Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Prospective
Official Title: IMPlementation of gUideLines for the Management of Arterial hypertenSION. The IMPULSION Study

Resource links provided by NLM:

Further study details as provided by Hellenic Atherosclerosis Society:

Primary Outcome Measures:
  • Efficacy in arterial hypertension control [ Time Frame: 6 months ] [ Designated as safety issue: No ]
  • Efficacy in reducing estimated risk of coronary heart disease [ Time Frame: 6 months ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Cost effectiveness of arterial hypertension control [ Time Frame: 6 months ] [ Designated as safety issue: No ]
  • Differences between primary and secondary health care settings as well as teaching hospitals [ Time Frame: 6 months ] [ Designated as safety issue: No ]

Estimated Enrollment: 1000
Study Start Date: November 2006
Study Completion Date: November 2007
Primary Completion Date: November 2007 (Final data collection date for primary outcome measure)
Detailed Description:

Physicians from 20 hospitals and 40 health centres (primary health care settings) were trained to implement guidelines in treating arterial hypertension.

There will be a baseline recording of patients with arterial hypertension and then physicians will have to complete a one page form (by ticking pre-specified boxes) about the baseline status of the patients and will have to report the measures they took to improve awareness, treatment, and effective control of arterial hypertension. After a six month effort, physicians will have to complete the same form at study completion. Previous training of physicians and the fact that they will have to report their success in treating hypertension will hopefully contribute to an increase in number of hypertensive patients at blood pressure target, and will minimise the target organ damage. The estimated reduction in coronary heart disease risk will be evaluated by a comparison of this risk (as evaluated by a risk engine, i.e. PROCAM) at study completion with that of baseline.


Ages Eligible for Study:   18 Years to 75 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Arterial hypertension as defined by the JNC 7 report

Exclusion Criteria:

  • Pregnancy
  • Lactation
  • Malignancies with small life expectancy
  • Unwillingness to participate
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00416611

Hellenic Atherosclerosis Society
Thessaloniki, Greece, 55132
Sponsors and Collaborators
Hellenic Atherosclerosis Society
Study Director: Athyros G Athyros, MD Clinical Trials Chair of Hellenic Atherosclerosis Society
  More Information

Responsible Party: Hellenic Atherosclerosios Society, V. Athyros, MD member of Advisdory Board of Hellenic Atherosclerosios Society Identifier: NCT00416611     History of Changes
Other Study ID Numbers: HAS-02-231206 
Study First Received: December 23, 2006
Last Updated: January 28, 2009
Health Authority: Greece: Ministry of Health and Welfare

Keywords provided by Hellenic Atherosclerosis Society:
High blood pressure
Effective Control
Coronary heart disease risk reduction

Additional relevant MeSH terms:
Cardiovascular Diseases
Vascular Diseases processed this record on April 27, 2016